| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
340,203,000 |
| Market
Cap: |
3.61(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.975 - $14.52 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering medicines for diseases. Co.'s gene therapy portfolio pipeline include Pompe disease, Fabry disease, CDKL5 deficiency disorder, ceroid lipofuscinosis, neuronal, Mucopolysaccharidosis Type IIIB, as well as a program in Mucopolysaccharidosis Type IIIA. Co.'s collaboration with University of Pennsylvania also provides Co. with disease-specific access and option rights to develop new gene therapy platform technologies and programs for most lysosomal disorders and a portfolio of other rare diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
185,169 |
532,450 |
719,592 |
1,444,335 |
| Total Sell Value |
$2,429,892 |
$7,066,289 |
$9,441,998 |
$17,793,526 |
| Total People Sold |
5 |
7 |
7 |
9 |
| Total Sell Transactions |
12 |
32 |
51 |
101 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Crowley John F |
Executive Chairman |
• • – |
2023-09-01 |
4 |
S |
$12.98 |
$78,447 |
D/D |
(6,044) |
920,053 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-09-01 |
4 |
S |
$12.97 |
$234,648 |
D/D |
(18,093) |
792,161 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-09-01 |
4 |
OE |
$2.94 |
$34,398 |
D/D |
11,700 |
810,254 |
|
- |
|
| Harford Simon N.r. |
Chief Financial Officer |
• – – |
2023-08-21 |
4 |
A |
$0.00 |
$0 |
D/D |
106,973 |
106,973 |
|
- |
|
| Prout Samantha |
Chief Accounting Officer |
• – – |
2023-08-17 |
4 |
D |
$12.77 |
$94,907 |
D/D |
(7,432) |
129,571 |
|
- |
|
| Castelli Jeff |
Chief Development Officer |
• – – |
2023-08-17 |
4 |
D |
$12.77 |
$185,931 |
D/D |
(14,560) |
368,593 |
|
- |
|
| Crowley John F |
Executive Chairman |
• • – |
2023-08-15 |
4 |
S |
$13.03 |
$78,734 |
D/D |
(6,044) |
926,097 |
|
- |
|
| Prout Samantha |
Chief Accounting Officer |
• – – |
2023-08-09 |
4 |
S |
$14.01 |
$516,933 |
D/D |
(36,909) |
137,003 |
|
- |
|
| Prout Samantha |
Chief Accounting Officer |
• – – |
2023-08-09 |
4 |
OE |
$9.55 |
$407,116 |
D/D |
36,909 |
173,912 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-08-01 |
4 |
S |
$13.39 |
$267,874 |
D/D |
(20,000) |
798,554 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-08-01 |
4 |
OE |
$2.94 |
$34,398 |
D/D |
11,700 |
818,554 |
|
- |
|
| Crowley John F |
Executive Chairman |
• • – |
2023-08-01 |
4 |
S |
$13.35 |
$80,716 |
D/D |
(6,044) |
932,141 |
|
- |
|
| Crowley John F |
Executive Chairman |
• • – |
2023-07-17 |
4 |
S |
$13.45 |
$81,263 |
D/D |
(6,044) |
938,185 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-07-13 |
4 |
S |
$12.51 |
$85,091 |
D/D |
(6,800) |
806,854 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-07-12 |
4 |
S |
$12.51 |
$18,759 |
D/D |
(1,500) |
813,654 |
|
- |
|
| Prout Samantha |
Chief Accounting OfficerOffice |
• – – |
2023-07-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
137,003 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-07-03 |
4 |
S |
$12.31 |
$144,016 |
D/D |
(11,700) |
815,154 |
|
- |
|
| Campbell Bradley L |
President & CEO |
• • – |
2023-07-03 |
4 |
OE |
$2.94 |
$34,398 |
D/D |
11,700 |
826,854 |
|
- |
|
| Crowley John F |
Executive Chairman |
• • – |
2023-07-03 |
4 |
S |
$12.31 |
$74,406 |
D/D |
(6,044) |
944,229 |
|
- |
|
| Raab Michael |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
68,596 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
59,289 |
|
- |
|
| Kelly Michael Aaron |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
40,207 |
|
- |
|
| Sblendorio Glenn |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
95,303 |
|
- |
|
| Whitman Burke W |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
86,337 |
|
- |
|
| Roberts Eiry |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,584 |
44,014 |
|
- |
|
1464 Records found
|
|
Page 5 of 59 |
|
|
0.28 (2.71%) 
